I concur, Guts. The sequence of the monthly results for this year is beyond impressive. I simply don't believe it will top out at current levels or just above. Also, Celtics' fundamental point about the impact of becoming cash-flow positive carries a great deal of weight. There is also the bonus that corresponds to the prospect of Rapimeds beginning to kick in soon. Most of the posters on this board realize that SCRC is deeply undervalued at its current levels simply on the basis of the compounding side.